Reversible Parkinsonism linked to trimetazidine (continued).
(1) In a series of 128 neurological patients taking trimetazidine, 56 developed motor disorders that improved or resolved when trimetazidine was withdrawn. (2) New cases of parkinsonism, gait disorders and tremor that resolved or improved after trimetazidine withdrawal have been reported in France. (3) As there is no evidence that trimetazidine is effective, there is no justification for placing patients at risk for parkinsonism. (4) Patients who develop motor disorders while taking trimetazidine have everything to gain and nothing to lose by discontinuing treatment. There is no possible justification for initiating treatment with trimetazidine.
D005602:France; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D016896:Treatment Outcome; D014292:Trimetazidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D014665:Vasodilator Agents; D014292:Trimetazidine